Novartis AG Slashes Executives' Pay Amidst Japan Studies Scandal

Published: Oct 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

To what extent the Diovan scandal in Japan will hurt Novartis remains unclear, but one executive concedes that the mess is not going to burnish the corporate reputation. The acknowledgement comes after a government panel earlier this week found the drugmaker may have violated Japanese law by using faulty data to promote its widely used heart drug, an offense that could lead to various penalties. In his second set of public remarks in the past week, David Epstein, who heads the Novartis pharmaceutical business, again apologized and also noted Diovan sales have fallen in Japan.

Help employers find you! Check out all the jobs and post your resume.

Back to news